A number of other countries have implemented changes in law that significantly reduce the extent of criminalization of marijuana use. Only in Australia and the Netherlands have there been any changes on the criminalization of the supply side and in neither of those countries is it legal to both produce and sell the drug. The relaxations so far, with the exception of the Netherlands, have not been very great i.e. have not much changed the legal risks faced by a user of marijuana. Thus it is perhaps not surprising that the changes in prevalence of use have not been substantial. This paper provides a brief review of the changes that have been tried outside the US. The emphasis is on the nature of the changes and how they have been implemented rather than on outcomes.
Les Clubs Sociaux du Cannabis (CSC) sont des associations d’usagers qui s’organisent pour s’auto-approvisionner sans avoir recours au marché noir. Profitant de une zone grise juridique, il existe depuis plusieurs années, des clubs privés qui produisent du cannabis pour le distribuer, sans but lucratif et en circuit fermé, à des consommateurs adultes.
Cannabis social clubs (CSC) are noncommercial organisations of users who get together to cultivate and distribute enough cannabis to meet their personal needs without having to turn to the black market. They are based on the fact that the consumption of illegal drugs has never been considered a crime under Spanish legislation. Taking advantage of this grey area, private clubs that produce cannabis for non-profit distribution solely to a closed group of adult members have existed for years.
This study brings together available evidence to provide a comprehensive analysis of cannabis production and markets across the EU. It combines information from EMCDDA routine reporting — data on patterns of prevalence and use, seizures, police reports, drug-law offences, cannabis potency and retail market prices — with literature on cannabis markets to create an in-depth analysis of the issue in a European context.
Three United Nations Conventions provide the international legal framework on drug control, instructing countries to limit drug supply and use to medical and scientific purposes. Yet, debate continues on the decriminalisation, or even legalisation, of drugs, particularly cannabis. Models under development for the legal supply of cannabis are described in this analysis, as well as some of the questions they raise.
Part of the ‘Perspectives on drugs’ (PODs) series, launched alongside the annual European Drug Report, these designed-for-the-web interactive analyses aim to provide deeper insights into a selection of important issues.
This is a guide to regulating legal markets for the non-medical use of cannabis. It is for policy makers, drug policy reform advocates and affected communities all over the world, who are witnessing the question change from, 'Should we maintain cannabis prohibition?' to 'How will legal regulation work in practice?
This RAND report provides an overview of the changes to laws and policies pertaining to cannabis in different countries. Several jurisdictions have reduced the penalties for possessing cannabis for personal use (and in some places even for home cultivation), while some jurisdictions have taken more dramatic steps and changed their laws and practices with respect to producing and distributing cannabis.
Cannabis was condemned by the 1961 Single Convention on Narcotic Drugs as a psychoactive drug with “particularly dangerous properties” and hardly any therapeutic value. Ever since, an increasing number of countries have shown discomfort with the treaty regime’s strictures through soft defections, stretching its legal flexibility to sometimes questionable limits.
This briefing is a preliminary sketch of the legal landscape for cannabis social clubs in Spain. Its author is presently conducting legal analysis and empirical research in Spain and her findings will be published in due course. The aim of this briefing is to provide an interim sketch of the relevant law for English speakers working in drug policy.